NWPF

News ArchivesRead News

Parkinson’s Drug Trial Has Researchers Optimistic

Thursday July 31, 2014

Mofina Thomas

Chicago Sun Times - Results of a Phase I clinical trial of what could be the first vaccine for Parkinson’s disease has experts cautiously optimistic.

Those results were released Thursday by the maker of the drug and the Michael J. Fox Foundation for Parkinson’s Disease.

The disease, a progressive disorder of the nervous system that affects movement, is believed to be caused by abnormal deposits in the brain of a protein that helps nerve cells talk to each other.

Many drugs can make movement easier or alleviate other symptoms of the disease. But no drug has been shown to effectively slow or stop the progression.

The drug being tested is known as PD01A, made by AFFiRiS AG, an Austria-based biotech company. It is supposed to stimulate the body’s immune system to produce antibodies that bind to the protein alpha-synuclein, clearing it from the brain and slowing disease progression.

Phase 1 looked only at whether PD01A was safe and tolerable to the relatively small sample of 32 people with Parkinson’s disease. The drug passed that test.

It was also found to generate alpha-synuclein-specific antibodies in 50 percent of the patients. If that is duplicated on a larger population, it could be a breakthrough for Parkinson’s disease.

“A treatment that could slow or stop Parkinson’s progression would be a game-changer for the five million worldwide living with this disease and the many more who will become at risk as our population ages,” Todd Sherer, CEO of the Michael J. Fox Foundation, said in a statement. The most recent drug trial “is one of the most promising efforts toward that goal.”

Dr. Christopher Goetz, director of the Parkinson’s Disease and Movement Disorders Center at Rush University Medical Center, agreed Phase I of PD01A is “very promising.”

But Goetz, who was not involved in the study, also cautioned that because testing of this drug is in the early stages, it remains to be seen whether increasing antibodies to fight alpha-synuclein actually does anything to effectively treat Parkinson’s disease.

Indeed, not everyone is convinced of that premise. And the findings are considered preliminary because they haven’t been published in a peer-reviewed medical journal.

Dr. Jose Biller, chair of the neurology department at Loyola Medicine, said he was cautiously optimistic at what could wind up being a “significant advance” in how Parkinson’s disease is treated.

“The basic science that is behind this trial is quite robust. And therefore, while nobody can talk about guarantee ….I think that it is a very cogent approach,” he said.

That said, though, Biller, who was not involved in the study, said, “We need to wait for the [follow-up] results.”

The next study will take place in Vienna and focus on assessing the immunological and clinical effects of a boost vaccination. Recruitment is expected to begin September.

http://www.suntimes.com/news/metro/28964893-418/drug-trial-has-parkinsons-researchers-cautiously-optimistic.html#.U-kZS7Evd3A

Recent News

May 20 - Book Review: Aging in the Key of Humor
May 19 - Press Release: The Michael J. Fox Foundation for Parkinson's Research Joins Multinational Critical Path for Parkinson's Consortium
May 19 - Congress reaches deal to overhaul chemical regulation
May 16 - Lifestyle: Why Parkinson's disease won't stop me rowing across the Pacific
May 16 - Many biomarkers for PD fail to inform on progression
May 10 - Parkinson's Cell Transplant Shows Good Reinnervation at 24 Years
May 7 - Growing art installation gathers stories of living with Parkinson's
May 5 - New technique can provide better cell transplants against Parkinson's disease
May 2 - What's Good For The Heart Is Good For The Brain
Apr 29 - Press Release: FDA approves first drug to treat hallucinations and delusions associated with Parkinson’s disease
Apr 28 - Dopamine-making neurons can be chemically controlled in animal model of Parkinson's
Apr 25 - Lifestyle: Dating with Disease
Apr 25 - Scientific breakthrough in fight against Parkinson's and Alzheimer's
Apr 20 - Breakthrough Parkinson's disease blood test
Apr 15 - Living with Parkinson's
Apr 12 - Tissue biomarker for dementia with Lewy bodies and Parkinson’s disease
Apr 11 - Yoga for Every Body: Experts say yoga can ease pain and improve mobility for people with neurologic conditions
Apr 9 - Commonly prescribed Parkinson's drugs up risk of compulsive gambling, shopping, binge eating, hypersexuality
Apr 7 - Pfizer and IBM Launch Innovative Research Project to Transform Parkinson's Disease Care
Apr 7 - Parkinson's Drug Highly Effective for Resistant Depression